Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

154.98 +3.17 (+2.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
50 51 Next >
News headline image
Why Is Hookipa Pharma (HOOK) Stock Up 81% Today? ↗
Hookipa Pharma stock is rising higher on Thursday as investors react to a purchase agreement for 15 million shares of HOOK. 
Via InvestorPlace
News headline image
RedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against Ebola ↗
RedHill Biopharma Ltd (NASDAQ: RDHL) says opaganib and RHB-107 (upamostat) demonstrated robust synergistic effects when combined individually with Gilead Sciences Inc (NASDAQ: GILD) Veklury... 
Via Benzinga
News headline image
QQQ And QQQM ETFs Top Gainers And Laggards Of 2023 ↗
This article will look at the top gainers and laggards of the two popular ETFs, which have over $17 billion and $223 billion assets, respectively. The two funds are similar, with the only difference... 
Via Talk Markets
Topics ETFs
News headline image
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy... 
Via Benzinga
News headline image
(GILD) - Analyzing Gilead Sciences's Short Interest ↗
 
Via Benzinga
News headline image
A Look Into Gilead Sciences Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? ↗
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the  
Via Benzinga
News headline image
Why Is Compugen (CGEN) Stock Up 189% Today? ↗
Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences. 
Via InvestorPlace
News headline image
Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy. ↗
Lilly's weight loss drug appears to be on the way to becoming a megablockbuster. 
Via The Motley Fool
News headline image
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. 
Via InvestorPlace
News headline image
NASDAQ:GILD is probably undervalued for the fundamentals it is displaying. ↗
Investors should take notice ofGILEAD SCIENCES INC (NASDAQ:GILD)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today ↗
 
Via Benzinga
News headline image
Looking Into Gilead Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today ↗
 
Via Benzinga
News headline image
A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street ↗
There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions ↗
Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion... 
Via Benzinga
News headline image
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks ↗
Regulators are already on the case, and their findings will have financial impacts. 
Via The Motley Fool
News headline image
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy ↗
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. 
Via InvestorPlace
News headline image
Is NASDAQ:GILD suited for dividend investing? ↗
Why the dividend investor may take a look at GILEAD SCIENCES INC (NASDAQ:GILD). 
Via Chartmill
News headline image
Gilead Sciences's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making ↗
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments. 
Via InvestorPlace
News headline image
2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off. 
Via The Motley Fool
News headline image
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies ↗
Tuesday, the FDA said it received reports of patients developing T-cell malig 
Via Benzinga
News headline image
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later ↗
There's no time like the present to buy these stocks. 
Via The Motley Fool
News headline image
Stocks Stall On November 21, 2023, As Systematic Flows Abate ↗
Stocks finished the day lower by roughly 20 bps, which is not a big deal, as rates fell somewhat and the dollar rallied 
Via Talk Markets
News headline image
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug ↗
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative... 
Via Benzinga
News headline image
In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals. ↗
GILEAD SCIENCES INC (NASDAQ:GILD): good value for what you're paying. 
Via Chartmill
News headline image
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead ↗
The companies will work together on treatments for multiple myeloma and lymphomas. 
Via Investor's Business Daily
News headline image
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review ↗
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.